Ideaya Biosciences (United States)

company in South San Francisco, United States

IDYA Nasdaq SEC CIK 1676725
Follow Ideaya Biosciences (United States) Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $10.2M −95.1% vs same quarter last year
Net income −$125.7M −205.5% vs same quarter last year
EPS, diluted −$1.22 −191.7% vs same quarter last year
Operating cash flow −$93.5M −165.7% vs same quarter last year
Revenue by quarter
$7M
$207.8M
$10.9M
$6.6M
$8.9M
$10.2M
Q4 24 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$400M−$200M$0$200M$400MFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$218.7M−$113.7M
FY24$7M−$274.5M
FY23$23.4M−$113M
FY22$50.9M−$58.7M
FY21$27.9M−$49.8M
FY20$19.5M−$34.5M
FY19$0−$42M
FY18-−$34.3M
FY17-−$11.9M
FY16--
MarginsShare of revenue
  • Operating margin
  • Net margin
−6000%−4000%−2000%0%FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−72.8%−52%
FY24−4671.1%−3921.1%
FY23−574.9%−483%
FY22−122.7%−115.2%
FY21−179.9%−178.1%
FY20−180.9%−176.6%
FY19--
FY18--
FY17--
FY16--
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0$100MFY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$73.5M
FY24−$251.4M
FY23−$117.6M
FY22−$90.6M
FY21−$58.4M
FY20$55M
FY19−$40.7M
FY18−$29.3M
FY17−$14M
FY16-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Ideaya Biosciences (United States)
  • Healthcare median
−4000%−3000%−2000%−1000%0%FY17FY19FY21FY23FY25
Show the numbers
YearIdeaya Biosciences (United States)Healthcare median
FY25−52%−30.6%
FY24−3921.1%−47%
FY23−483%−58%
FY22−115.2%−80.4%
FY21−178.1%−71.8%
FY20−176.6%−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%
FY16-−36%